Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | £891 | £3,388 | £4,732 | £2,963 |
| % Growth | -73.7% | -28.4% | 59.7% | – |
| Cost of Goods Sold | £687 | £1,937 | £2,922 | £1,652 |
| Gross Profit | £204 | £1,451 | £1,810 | £1,310 |
| % Margin | 22.9% | 42.8% | 38.3% | 44.2% |
| R&D Expenses | £2,321 | £1,993 | £4,242 | £5,860 |
| G&A Expenses | £8,670 | £12,481 | £9,302 | £5,730 |
| SG&A Expenses | £11,085 | £13,343 | £10,312 | £6,313 |
| Sales & Mktg Exp. | £2,415 | £863 | £1,009 | £583 |
| Other Operating Expenses | -£13,203 | -£13,601 | -£8,502 | -£5,003 |
| Operating Expenses | £204 | £1,451 | £1,810 | £1,310 |
| Operating Income | -£16,700 | -£15,598 | -£14,261 | -£12,070 |
| % Margin | -1,874.1% | -460.4% | -301.4% | -407.4% |
| Other Income/Exp. Net | £713 | -£5,533 | -£6,506 | -£111 |
| Pre-Tax Income | -£17,548 | -£21,132 | -£20,768 | -£15,437 |
| Tax Expense | £0 | £2 | £0 | -£27 |
| Net Income | -£17,531 | -£20,824 | -£20,347 | -£15,870 |
| % Margin | -1,967.4% | -614.6% | -430% | -535.6% |
| EPS | -0.47 | -7.11 | -7.63 | -7.01 |
| % Growth | 93.4% | 6.8% | -8.8% | – |
| EPS Diluted | -0.47 | -7.07 | -7.63 | -6.95 |
| Weighted Avg Shares Out | 37,013 | 2,931 | 2,667 | 2,263 |
| Weighted Avg Shares Out Dil | 37,012 | 2,947 | 2,667 | 2,285 |
| Supplemental Information | – | – | – | – |
| Interest Income | £2 | £0 | £0 | £8 |
| Interest Expense | £482 | £257 | £210 | £369 |
| Depreciation & Amortization | £1,294 | £752 | £248 | £491 |
| EBITDA | -£15,772 | -£20,122 | -£20,310 | -£14,576 |
| % Margin | -1,770% | -593.9% | -429.2% | -491.9% |